Developer docs
API playgroundTry for free, no card

Search company profiles

Serán Bioscience

Full company profile

uuid0000wlr

Namestring
Serán Bioscience
Legal namestring
Serán BioScience, LLC
Websiteurl
seranbio.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBend, United States
HQ citystring
Bend
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug development services, contract manufacturing, oral solid dosage, spray drying, pharmaceutical formulation
Industry3 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Contract Development and Manufacturing
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Serán operates as a CDMO providing fee-for-service drug development and manufacturing to pharmaceutical and biotechnology companies. Services span from preclinical formulation through commercial-scale manufacturing of oral solid dose products. Revenue is generated through project-based contracts, time-and-materials arrangements, and potentially milestone-based payments for development programs.

seranbio.com
2Commercial Manufacturing
TypeManaged Services
Description

Upon completion of the commercial manufacturing facility (Q2 2027), Serán will provide large-scale commercial production of oral solid dose pharmaceuticals. Revenue will be generated through long-term manufacturing contracts with pharmaceutical companies.

seranbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Serán Bioscience is a science-driven CDMO providing integrated drug product development, formulation, and manufacturing services for oral solid dosage forms. Services span preformulation and API characterization, formulation development, dosage form design, spray drying and particle engineering for bioavailability enhancement, cGMP clinical manufacturing across 14 ISO 8 classified suites, analytical and quality control, and full-scale commercial manufacturing of small molecules and biologics. The company serves pharmaceutical and biotechnology clients from preclinical through commercial-scale production.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Scale-up from preclinical to commercial with material-sparing approaches using only milligram quantities of API for early development
+2 more records
Product overview1 text field

Serán Bioscience is a science-driven Contract Development and Manufacturing Organization (CDMO) that provides integrated drug product development, formulation, and manufacturing solutions. The company operates eight core service offerings: Commercial Manufacturing (full-scale oral solid dose production with validation and tech transfer), Preformulation Services (API characterization), Formulation Development (QbD/DoE-driven oral solid dosage forms), Dosage Form Development (capsules, tablets, powder-in-bottle), Spray Drying and Particle Engineering (bioavailability enhancement via amorphous solid dispersions), cGMP Manufacturing (clinical production in ISO 8 suites), Analytical + Quality Control (method development and release testing), and Spray Drying of Biologics (biotherapeutic formulations). These services span from early discovery through commercial-scale production, enabling complex oral, pulmonary, and nasal drug delivery across small molecules and biologics.

Product and service8 records
1Commercial Manufacturing
CategoryManufacturing Services
Description

Full-scale commercial manufacturing of oral solid dosage forms with lifecycle-based process validation, technology transfer, scale-up services, and capabilities including spray drying, granulation, tableting, encapsulation, and coating. Designed for pharmaceutical and biotechnology companies advancing drug products through commercial launch and supply.

2Preformulation Services
CategoryDevelopment Services
Description

API characterization services including solid-state properties assessment, solubility screening, particle size analysis, dissolution studies, multifactorial stability screening, and preclinical formulation development. Used by pharmaceutical and biotech clients to understand molecule behavior early in development.

3Formulation Development
CategoryDevelopment Services
Description

Oral solid dosage form development engineered to meet solubility and release challenges using QbD and DoE principles, supporting preclinical through Phase III studies with material-sparing approaches. Targeted at pharmaceutical and biotechnology companies developing complex molecules.

4Dosage Form Development
CategoryDevelopment Services
Description

Development of solid dosages including capsules, tablets, and powder-in-bottle formulations engineered for solubility challenges and extended-release mechanisms with phase-appropriate strategies. Serves pharmaceutical and biotech clients across preclinical to clinical development stages.

5Spray Drying and Particle Engineering
CategoryManufacturing Services
Description

Bioavailability enhancement through spray drying for amorphous solid dispersions, with capabilities ranging from nanometers to hundreds of microns in particle size, supporting preclinical through commercial scale. Addresses poor solubility challenges for pharmaceutical and biotechnology clients.

6cGMP Manufacturing
CategoryManufacturing Services
Description

Clinical manufacturing capabilities for oral solid dosage forms including spray drying, hot melt extrusion, blending, milling, granulation, encapsulation, tablet compression, coating, and clinical packaging in ISO 8 classified suites. Serves pharmaceutical and biotech clients requiring Phase I-III clinical supply.

7Analytical + Quality Control
CategoryQuality Control Services
Description

State-of-the-art analytical laboratories supporting formulation development and cGMP quality control including method transfer, development, qualification, ICH stability testing, and environmental monitoring. Supports pharmaceutical and biotech clients with method development, validation, and release testing needs.

8Spray Drying of Biologics
CategoryManufacturing Services
Description

Spray drying expertise for biotherapeutic formulations including peptides, proteins, phages, and nucleic acids, enabling high-concentration protein suspensions, pulmonary delivery, and improved stability. Designed for pharmaceutical and biotechnology companies developing biologic drug products.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-01-01
Description

Construction partner for the new commercial manufacturing campus in Bend, Oregon. Celebrated groundbreaking with Serán's Board of Directors and leadership.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-01-01
Description

Design and construction partner for the new commercial manufacturing facility campus in Bend, Oregon.

3Blaise Cacciola (BCA)
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-01-01
Description

Partner involved in the construction and design of the commercial manufacturing campus.

seranbio.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CDMO leader with extensive oral solid dose and spray drying capabilities, including the former Bend Research operations that share lineage with Serán's Bend, Oregon expertise. Lonza competes across the full CDMO value chain Serán targets.

TypeDirect peer
Description

UK-based CDMO specializing in formulation development, clinical manufacturing, and integrated drug substance-to-drug product services for small molecules. Closely comparable service offering and customer base to Serán.

TypeDirect peer
Description

US-based CDMO offering formulation development, analytical services, and small-batch clinical manufacturing for oral solid dose and sterile products. A comparable mid-sized competitor in clinical-stage CDMO services.

TypeDirect peer
Description

Specialty CDMO with deep expertise in spray drying, particle engineering, and bioavailability enhancement for small molecules. Hovione competes directly with Serán's core spray-dried dispersion and amorphous solid dispersion offerings.

TypeBroad incumbent
Description

Global CDMO services through Eurofins CDMO (formerly Alphapanel / Amatsigroup) offering formulation development, clinical manufacturing, and analytical services comparable to Serán's offerings.

TypeOthers
Description

Regulatory and development services provider serving similar pharma/biotech customers. Adjacent rather than directly competitive, but relevant context for the CDMO services ecosystem Serán operates in.

TypeEmerging player
Description

Smaller specialty CDMO focused on poorly soluble drugs and complex formulations including nanoemulsions, hot melt extrusion, and spray drying. Comparable technology stack but smaller scale than Serán.

TypeBroad incumbent
Description

Large diversified CDMO with significant oral solid dose and bioavailability enhancement capabilities including OptiMelt hot melt extrusion and similar formulation services. Competes for the same pharma and biotech clients Serán targets.

TypeBroad incumbent
Description

Through its Patheon CDMO business, Thermo Fisher is one of the largest global CDMOs with comprehensive oral solid dose development, clinical, and commercial manufacturing capabilities that overlap Serán's offering.

TypeEmerging player
Description

CDMO with proprietary 3D-printed drug delivery technology and formulation development services for complex oral dosage forms. Adjacent competitor in novel oral drug delivery CDMO services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Serán Bioscience

Pharmaceutical Contract Development and Manufacturingseranbio.com

Serán Bioscience firmographics

Firmographics
Name
Serán Bioscience
Legal name
Serán BioScience, LLC
Website
https://seranbio.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Serán Bioscience industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Drug development services
  • Contract manufacturing
  • Oral solid dosage
  • Spray drying
  • Pharmaceutical formulation

Where Serán Bioscience is headquartered

Location

Headquarters

HQ city
Bend
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Serán Bioscience business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing Services: Serán operates as a CDMO providing fee-for-service drug development and manufacturing to pharmaceutical and biotechnology companies. Services span from preclinical formulation through commercial-scale manufacturing of oral solid dose products. Revenue is generated through project-based contracts, time-and-materials arrangements, and potentially milestone-based payments for development programs.
  2. Commercial Manufacturing: Upon completion of the commercial manufacturing facility (Q2 2027), Serán will provide large-scale commercial production of oral solid dose pharmaceuticals. Revenue will be generated through long-term manufacturing contracts with pharmaceutical companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Serán Bioscience product offering

Product offering

Core offering

Serán Bioscience is a science-driven CDMO providing integrated drug product development, formulation, and manufacturing services for oral solid dosage forms. Services span preformulation and API characterization, formulation development, dosage form design, spray drying and particle engineering for bioavailability enhancement, cGMP clinical manufacturing across 14 ISO 8 classified suites, analytical and quality control, and full-scale commercial manufacturing of small molecules and biologics. The company serves pharmaceutical and biotechnology clients from preclinical through commercial-scale production.

Product overview

Serán Bioscience is a science-driven Contract Development and Manufacturing Organization (CDMO) that provides integrated drug product development, formulation, and manufacturing solutions. The company operates eight core service offerings: Commercial Manufacturing (full-scale oral solid dose production with validation and tech transfer), Preformulation Services (API characterization), Formulation Development (QbD/DoE-driven oral solid dosage forms), Dosage Form Development (capsules, tablets, powder-in-bottle), Spray Drying and Particle Engineering (bioavailability enhancement via amorphous solid dispersions), cGMP Manufacturing (clinical production in ISO 8 suites), Analytical + Quality Control (method development and release testing), and Spray Drying of Biologics (biotherapeutic formulations). These services span from early discovery through commercial-scale production, enabling complex oral, pulmonary, and nasal drug delivery across small molecules and biologics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Commercial Manufacturing Full-scale commercial manufacturing of oral solid dosage forms with lifecycle-based process validation, technology transfer, scale-up services, and capabilities including spray drying, granulation, tableting, encapsulation, and coating. Designed for pharmaceutical and biotechnology companies advancing drug products through commercial launch and supply.
  • Preformulation Services API characterization services including solid-state properties assessment, solubility screening, particle size analysis, dissolution studies, multifactorial stability screening, and preclinical formulation development. Used by pharmaceutical and biotech clients to understand molecule behavior early in development.
  • Formulation Development Oral solid dosage form development engineered to meet solubility and release challenges using QbD and DoE principles, supporting preclinical through Phase III studies with material-sparing approaches. Targeted at pharmaceutical and biotechnology companies developing complex molecules.
  • Dosage Form Development Development of solid dosages including capsules, tablets, and powder-in-bottle formulations engineered for solubility challenges and extended-release mechanisms with phase-appropriate strategies. Serves pharmaceutical and biotech clients across preclinical to clinical development stages.
  • Spray Drying and Particle Engineering Bioavailability enhancement through spray drying for amorphous solid dispersions, with capabilities ranging from nanometers to hundreds of microns in particle size, supporting preclinical through commercial scale. Addresses poor solubility challenges for pharmaceutical and biotechnology clients.
  • cGMP Manufacturing Clinical manufacturing capabilities for oral solid dosage forms including spray drying, hot melt extrusion, blending, milling, granulation, encapsulation, tablet compression, coating, and clinical packaging in ISO 8 classified suites. Serves pharmaceutical and biotech clients requiring Phase I-III clinical supply.
  • Analytical + Quality Control State-of-the-art analytical laboratories supporting formulation development and cGMP quality control including method transfer, development, qualification, ICH stability testing, and environmental monitoring. Supports pharmaceutical and biotech clients with method development, validation, and release testing needs.
  • Spray Drying of Biologics Spray drying expertise for biotherapeutic formulations including peptides, proteins, phages, and nucleic acids, enabling high-concentration protein suspensions, pulmonary delivery, and improved stability. Designed for pharmaceutical and biotechnology companies developing biologic drug products.

Quantifiable outcome

  • Scale-up from preclinical to commercial with material-sparing approaches using only milligram quantities of API for early development
  • +2 more outcomes

Companies that use Serán Bioscience

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Serán Bioscience technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Serán Bioscience partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Mortenson ConstructioncoreImplementation/ SI/ Consulting Partner · 1 January 2025Construction partner for the new commercial manufacturing campus in Bend, Oregon. Celebrated groundbreaking with Serán's Board of Directors and leadership.
  • CRB GroupcoreImplementation/ SI/ Consulting Partner · 1 January 2025Design and construction partner for the new commercial manufacturing facility campus in Bend, Oregon.
  • Blaise Cacciola (BCA)minorImplementation/ SI/ Consulting Partner · 1 January 2025Partner involved in the construction and design of the commercial manufacturing campus.

Scale indicators8 records

Recent moves10 records

Expansion highlights5 records

Serán Bioscience competitors and assessment

Company assessment

Broad incumbents

  • Lonza: Global CDMO leader with extensive oral solid dose and spray drying capabilities, including the former Bend Research operations that share lineage with Serán's Bend, Oregon expertise. Lonza competes across the full CDMO value chain Serán targets.
  • Eurofins CDMO: Global CDMO services through Eurofins CDMO (formerly Alphapanel / Amatsigroup) offering formulation development, clinical manufacturing, and analytical services comparable to Serán's offerings.
  • Catalent: Large diversified CDMO with significant oral solid dose and bioavailability enhancement capabilities including OptiMelt hot melt extrusion and similar formulation services. Competes for the same pharma and biotech clients Serán targets.
  • Thermo Fisher Scientific (CDMO services): Through its Patheon CDMO business, Thermo Fisher is one of the largest global CDMOs with comprehensive oral solid dose development, clinical, and commercial manufacturing capabilities that overlap Serán's offering.

Direct peers

  • Quotient Sciences: UK-based CDMO specializing in formulation development, clinical manufacturing, and integrated drug substance-to-drug product services for small molecules. Closely comparable service offering and customer base to Serán.
  • Alcami: US-based CDMO offering formulation development, analytical services, and small-batch clinical manufacturing for oral solid dose and sterile products. A comparable mid-sized competitor in clinical-stage CDMO services.
  • Hovione: Specialty CDMO with deep expertise in spray drying, particle engineering, and bioavailability enhancement for small molecules. Hovione competes directly with Serán's core spray-dried dispersion and amorphous solid dispersion offerings.

Others

  • PharmaLex (now part of Cencora): Regulatory and development services provider serving similar pharma/biotech customers. Adjacent rather than directly competitive, but relevant context for the CDMO services ecosystem Serán operates in.

Emerging players

  • Ascendia Pharmaceuticals: Smaller specialty CDMO focused on poorly soluble drugs and complex formulations including nanoemulsions, hot melt extrusion, and spray drying. Comparable technology stack but smaller scale than Serán.
  • Aprecia Pharmaceuticals: CDMO with proprietary 3D-printed drug delivery technology and formulation development services for complex oral dosage forms. Adjacent competitor in novel oral drug delivery CDMO services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Serán Bioscience social profiles

Digital presence

Serán Bioscience compliance and trust

Trust signal

Compliance1 record

Serán Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Serán Bioscience leadership team

Management profile

Number of profiles

Profiles15 records

Serán Bioscience funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Serán Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Serán Bioscience

What does Serán Bioscience do?

Serán Bioscience is a science-driven CDMO providing integrated drug product development, formulation, and manufacturing services for oral solid dosage forms. Services span preformulation and API characterization, formulation development, dosage form design, spray drying and particle engineering for bioavailability enhancement, cGMP clinical manufacturing across 14 ISO 8 classified suites, analytical and quality control, and full-scale commercial manufacturing of small molecules and biologics. The company serves pharmaceutical and biotechnology clients from preclinical through commercial-scale production.

Is Serán Bioscience a public or private company?

Serán Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Serán Bioscience founded?

Serán Bioscience was founded in 2016. It employs 101 to 250 people.

Where is Serán Bioscience based?

Serán Bioscience is headquartered in Bend, United States, in the North America region.

How does Serán Bioscience make money?

Two revenue lines are on record. Contract Development and Manufacturing Services are the primary driver. The others are commercial Manufacturing.

Who are Serán Bioscience's main competitors?

Broad incumbents on record are Lonza, Eurofins CDMO, Catalent and Thermo Fisher Scientific (CDMO services). Direct peers are Quotient Sciences, Alcami and Hovione. PharmaLex (now part of Cencora) is listed as an others. Emerging players are Ascendia Pharmaceuticals and Aprecia Pharmaceuticals.

Does Serán Bioscience have an API?

No public API is recorded for Serán Bioscience.

What industry is Serán Bioscience in?

Serán Bioscience's product category is Pharmaceutical Contract Development and Manufacturing. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ConstructionownersBend Pharmaceutical Plant Completes Structural Framework, Eyes 200 JobsSerán Bioscience announced the completion of the structural framework for its new pharmaceutical manufacturing facility in northeast Bend, Oregon, marking a critical milestone in construction. The facility, expected to be fully operational by 2027, will manufacture and distribute prescription medications directly to pharmacies and patients, with company projections indicating approximately 200 jobs across manufacturing, quality assurance, engineering, and administrative roles. Local economic development officials have cited the project as evidence of Bend's growing life sciences and advanced manufacturing presence, building on the region's expanding biotech and pharmaceutical sector.ContractpharmaSerán Bioscience Plans New Commercial-Scale Manufacturing FacilitySerán Bioscience announced a growth transaction of over $200 million led by Bain Capital Life Sciences, with Vivo Capital remaining a key shareholder. The company will build a new commercial-scale manufacturing facility in Bend, Oregon, completed in 2026, supporting oral, pulmonary, and nasal delivery modalities. It plans to hire up to 150 additional employees as the campus expands to nearly 200,000 square feet.YahooSerán Bioscience Announces $200 Million Strategic Growth Transaction and Plans for New Commercial FacilitySerán Bioscience announced a strategic growth transaction exceeding $200 million, led by Bain Capital Life Sciences with Vivo Capital as a key shareholder. The deal funds a new commercial-scale manufacturing facility in Bend, Oregon, to be completed in 2026, supporting oral, pulmonary, and nasal delivery modalities. The company plans to hire up to 150 additional employees.Business Wire BlogSerán Bioscience Announces $200 Million Strategic Growth Transaction and Plans for New Commercial FacilitySerán Bioscience announced a strategic growth transaction of over $200 million led by Bain Capital Life Sciences, with Vivo Capital remaining a key shareholder. The deal funds a new commercial-scale manufacturing facility in Bend, Oregon, to be completed in 2026, supporting oral, pulmonary, and nasal delivery modalities. The company plans to hire up to 150 additional employees.PR NewswireSerán Bioscience Announces Investment by Vivo CapitalVivo Capital made a majority investment in Serán Bioscience, with founders retaining control. The funds will expand services, double clean room capacity by year-end, and build a new 50,000 ft2 cGMP facility by 2022. Serán has over 50 employees, mostly scientists.